Johnson & Johnson has signed a definitive agreement to acquire Shockwave Medical, the transaction of which is anticipated to conclude by the mid of 2024
As per the agreement, Johnson & Johnson will acquire all the Shockwave’s outstanding shares for $335.00 per unit making it a total deal value of ~$13.1B
Through the acquisition, the company will enhance the MedTech cardiovascular portfolio with its focus on two of the cardiovascular indications incl. coronary artery disease (CAD) and peripheral artery disease (PAD)
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson’s Opsynvi (macitentan and tadalafil) Receives the US FDA’s Approval for the Treatment of Pulmonary Arterial Hypertension
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
